Comparison - GENE - NASDAQ

Weiss Ratings	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Rating	E
Reward Index	Very Weak
Risk Index	Very Weak
Risk Grade	E+
Reward Grade	E

Rating Factors	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Dividend Index	--
Growth Index	Weak
Efficiency Index	Very Weak
Solvency Index	Good
Total Return Index	Very Weak
Volatility Index	Very Weak

Beta / Standard Deviation	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Beta	1.02

Price History	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
7-Day Total Return	--
30-Day Total Return	--
60-Day Total Return	--
90-Day Total Return	--
Year to Date Total Return	--
1-Year Total Return	--
2-Year Total Return	--
3-Year Total Return	--
5-Year Total Return	--
52-Week High % Change	--
52-Week Low % Change	--

Price	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
52-Week High Price	$3.59
52-Week Low Price	$0.67
52-Week Low Price (Date)	Oct 02, 2024
52-Week High Price (Date)	Apr 12, 2024

Valuation	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Market Cap	--
Enterprise Value	3.50M
Price/Earnings (TTM)	--
Earnings Per Share (TTM)	-0.06
Earnings Per Share Growth	--
Price/Earnings To Growth	--
Price/Sales (TTM)	18.00
Price/Book (Q)	83.15
Enterprise Value/Revenue (TTM)	--
Price	--
Enterprise Value/EBITDA (TTM)	--
Enterprise Value/EBIT	--
Market Cap Category	Nano Cap

Dividends and Shares	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Shares Outstanding	149.02M
Dividend Yield	--
Div. Per Share (Most Recent)	--
Dividend Per Share (TTM)	--
Payout Ratio (TTM)	--
Dividend Per Share (Most Recent)	--

Company Info	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Phone Number	61 3 8412 7000
Address	321 Chapel Street Prahran, VIC 3181
Website	genetype.com
Country	Australia
Year Founded	1987

Profitability	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Operating Margin (TTM)	-109.53%
Profit Margin	-124.20%

Management Effectiveness	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Return on Assets	-61.97%
Return on Equity	--

Income Statement	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Revenue (TTM)	5.03M
Total Revenue (TTM)	6.34M
Revenue Per Share	--
Gross Profit (TTM)	3.88M
EBITDA (TTM)	-6.60M
EBIT (TTM)	-6.95M
Net Income (TTM)	-7.88M
Net Income Avl. to Common (TTM)	-7.88M
Total Revenue Growth (Q YOY)	-11.83%
Earnings Growth (Q YOY)	12.21%
EPS Diluted (TTM)	-0.06
EPS Diluted Growth (Q YOY)	34.74%

Balance Sheet	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Cash and Short-Term Inv. (Q)	693.50K
Cash Per Share (Q)	$0.00
Total Current Assets (Q)	2.47M
Total Preferred Equity (Q)	--
Total Equity (Q)	1.22M
Current Ratio (Q)	0.881
Book Value Per Share (Q)	$0.01
Total Assets (Q)	4.13M
Total Current Liabilities (Q)	2.80M
Total Debt (Q)	583.90K
Total Liabilities (Q)	2.91M
Total Common Equity (Q)	1.22M

Cash Flow	GENE - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Cash from Investing (TTM)	75.20K
Cash from Financing (TTM)	1.86M
Net Change in Cash (TTM)	-4.48M
Levered Free Cash Flow (TTM)	-3.75M
Cash from Operations (TTM)	-6.35M